Collaborative Fund Advisors LLC Purchases Shares of 15,103 Royalty Pharma PLC $RPRX

Collaborative Fund Advisors LLC acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,103 shares of the biopharmaceutical company’s stock, valued at approximately $724,000.

Other large investors have also recently made changes to their positions in the company. LM Advisors LLC acquired a new position in Royalty Pharma during the fourth quarter worth $26,000. Blue Trust Inc. grew its stake in shares of Royalty Pharma by 173.4% in the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 437 shares in the last quarter. Lloyd Advisory Services LLC. acquired a new stake in shares of Royalty Pharma in the fourth quarter valued at $30,000. Private Trust Co. NA raised its holdings in shares of Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares during the period. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of Royalty Pharma by 66.4% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 446 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. UBS Group lifted their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Morgan Stanley boosted their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Citigroup raised their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $53.71.

Insider Buying and Selling

In related news, EVP Christopher Hite sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the sale, the executive vice president directly owned 559,399 shares in the company, valued at approximately $30,431,305.60. This represents a 21.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 64,399 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total transaction of $3,476,258.02. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 427,800 shares of company stock valued at $23,333,723. Corporate insiders own 18.84% of the company’s stock.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $57.77 on Monday. The stock has a market cap of $33.27 billion, a P/E ratio of 39.30, a PEG ratio of 1.59 and a beta of 0.43. The business’s fifty day simple moving average is $53.56 and its 200-day simple moving average is $47.30. Royalty Pharma PLC has a 12-month low of $34.08 and a 12-month high of $57.80. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The firm had revenue of $630.58 million during the quarter, compared to analysts’ expectations of $881.69 million. As a group, equities analysts predict that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were paid a $0.235 dividend. This represents a $0.94 annualized dividend and a dividend yield of 1.6%. The ex-dividend date was Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.